 |
|
| Liver cancer | Iodine  Metuximab injection (Licartin) targeting HAb18G/CD147 for liver cancer was approved by SFDA as State Class I New Drug in 2005. It is the first antibody drug for a novel target with intellectual property rights in China. |
CAR-T cell therapy | CAR T Cell Technology for PMBP proprietary tumor targets was implemented. |
Lung cancer Metuzumab  | Metuzumab is a novel monoclonal antibody targeting CD147 for the therapy of lung cancer, using ADCC enhancement technology. Metuzumab was approved IND by CFDA in 2015 and a phase I clinical trial has been implemented with 11 patients enrolled. A phase II clinical trial will be conducted in 2021. |
ADCC enhancement | ADCC enhancement of HAb18 by expression in proprietary CHO host cell line was achieved combined with a homogeneous glycosylation profile. |
ADC enhancement | Antibody drug conjugation was performed to improve the medical efficiency of monoclonal antibodies and antibody fragments for efficient tumor therapy. |
|
